Long term survival with adjuvant immunotherapy after neoadjuvant chemoimmunotherapy and esophagectomy in locally advanced ESCC

Postoperative adjuvant immunotherapy (aIT) represents a strategy for locally advanced esophageal squamous cell carcinoma (LA-ESCC) treated with neoadjuvant chemoimmunotherapy (nCIT) followed by esophagectomy. This multicenter retrospective cohort enrolled 418 Chinese LA-ESCC patients treated with nCIT followed by esophagectomy, split into aIT and surveillance groups. We balanced baseline confounders via 1:1 propensity score matching (PSM) and analyzed overall survival (OS) and event-free survival (EFS). With a median 48.7-month follow-up, aIT was associated with higher 4-year OS among matched patients (78.21% vs. 65.20%, HR=0.571, p = 0.012), while EFS (64.45% vs. 59.46%, HR=0.735, p = 0.114) showed no intergroup difference. The observed OS association with aIT was limited to patients without major pathological response (non-MPR). In this retrospective cohort, postoperative aIT was associated with longer overall survival specifically among non-MPR LA-ESCC patients following nCIT.

Authors

Institutions

Publication Details

Journal
iScience
Published
2026-11-19
DOI
https://doi.org/10.1016/j.isci.2026.118247
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long term survival with adjuvant immunotherapy after neoadjuvant chemoimmunotherapy and esophagectomy in locally advanced ESCC

Xiaomin Wang, Hong Ge, Bingxu Li, Baosheng Li et al.
5 links
iScience
Esophageal Cancer Research and Treatment
article

Long term survival with adjuvant immunotherapy after neoadjuvant chemoimmunotherapy and esophagectomy in locally advanced ESCC

Xiaomin Wang, Hong Ge, Bingxu Li, Baosheng Li, Wencheng Zhang, Huai Liu, Xiaoli Zheng, Shuhan Yang, Yumeng Xiao, Zifan Qin, Hui Wang, Wei Huang
article en

Abstract

Postoperative adjuvant immunotherapy (aIT) represents a strategy for locally advanced esophageal squamous cell carcinoma (LA-ESCC) treated with neoadjuvant chemoimmunotherapy (nCIT) followed by esophagectomy. This multicenter retrospective cohort enrolled 418 Chinese LA-ESCC patients treated with nCIT followed by esophagectomy, split into aIT and surveillance groups. We balanced baseline confounders via 1:1 propensity score matching (PSM) and analyzed overall survival (OS) and event-free survival (EFS). With a median 48.7-month follow-up, aIT was associated with higher 4-year OS among matched patients (78.21% vs. 65.20%, HR=0.571, p = 0.012), while EFS (64.45% vs. 59.46%, HR=0.735, p = 0.114) showed no intergroup difference. The observed OS association with aIT was limited to patients without major pathological response (non-MPR). In this retrospective cohort, postoperative aIT was associated with longer overall survival specifically among non-MPR LA-ESCC patients following nCIT.

iScienceVol. 29(12)
Central South University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Zhengzhou University (CN), Shandong Tumor Hospital (CN), Hunan Cancer Hospital (CN), Henan Cancer Hospital (CN), Anyang Tumor Hospital (CN), Shandong First Medical University (CN)
Good health and well-being
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon